NCT00826267 - 6 Weeks Treatment of Locally Advanced Breast Cancer With BIBW 2992 (Afatinib) or Lapatinib or Trastuzumab | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2009

Primary Completion Date

August 31, 2011

Conditions

Breast Neoplasms

Interventions

DRUG

lapatinib

lapatinib tablets 1500 mg daily

DRUG

BIBW 2992

BIBW 2992 high dose once daily (allowed dose reduction to medium or low once daily in case of AE)

DRUG

trastuzumab

trastuzumab 4mg/kg i.v. week 1, followed by 2mg/kg i.v. weekly

Trial Locations (17)

1200.44.01001 Boehringer Ingelheim Investigational Site, Houston

1200.44.12008 Boehringer Ingelheim Investigational Site, Brasília

1200.44.12011 Boehringer Ingelheim Investigational Site, Cachoeiro de Itapemirim

1200.44.12012 Boehringer Ingelheim Investigational Site, Campo Grande

1200.44.12009 Boehringer Ingelheim Investigational Site, Caxias do Sul

1200.44.12010 Boehringer Ingelheim Investigational Site, Goiânia

1200.44.12005 Boehringer Ingelheim Investigational Site, Ijuí

1200.44.12007 Boehringer Ingelheim Investigational Site, Natal

1200.44.12004 Boehringer Ingelheim Investigational Site, Novo Hamburgo

1200.44.12001 Boehringer Ingelheim Investigational Site, Porto Alegre

1200.44.12013 Boehringer Ingelheim Investigational Site, Porto Alegre

1200.44.14002 Boehringer Ingelheim Investigational Site, Bogotá

1200.44.14001 Boehringer Ingelheim Investigational Site, Santiago de Cali

1200.44.19005 Boehringer Ingelheim Investigational Site, Cercado

1200.44.19001 Boehringer Ingelheim Investigational Site, Lima

1200.44.19004 Boehringer Ingelheim Investigational Site, Lima

1200.44.19003 Boehringer Ingelheim Investigational Site, San Isidro